Israel's economic-social cabinet approved a modified version of a pharmaceutical intellectual property protection bill that may ease some objections by foreign drugmakers, though the U.S. is expected to object to the terms of the amended bill. The cabinet postponed action on a provision that would have enabled Israeli firms to begin developing generic drugs before foreign firms' patents expired in the country. The bill is to be attached to the 2005 budget law.

Full Story:
Globes (Israel)

Related Summaries